
Turning cancer cell dependencies into targeted therapies
Episode 205
Today I’m delighted to welcome Andy Parker, CEO of Step Pharma. With over 25 years of experience across AstraZeneca, Shire, Zealand Pharma, and venture capital, Andy has led Step Pharma since 2019. The company is pioneering a targeted approach to cancer and blood disorders by inhibiting the enzyme CTPS1. Their lead candidate, dencatistat, blocks this pathway that certain cancer cells and activated immune cells rely on, while sparing healthy cells that use the related CTPS2 enzyme. In this episode, we’ll dive into the science behind this mechanism, explore Step Pharma’s expanding pipeline from lymphomas and solid tumours to essential thrombocythaemia, and discuss their recent €38 million Series C financing. We’ll also look ahead to the future of precision oncology. 01:17 Meet Andy Parker 06:12 The biotech ecosystem around Geneva 07:51 The CTPS1 enzyme and why cancer cells depend on it 14:08 Pipeline-in-a-product strategy across three indications 20:14 The series C: €38 million raise 25:41 Partnering with big pharma: possibilities and limits 28:11 The future of precision oncology and metabolic targeting Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter To dive deeper into the topic: Step Pharma and Concr to partner on cancer treatment Step Pharma moves into oncology clinical trials Step Pharma announces promising pre-clinical cancer data
Publisher
Beyond Biotech - the podcast from Labiotech
Published
July 10, 2026
Duration
31 min
Format
Podcast
Category
Issues · Tech News
Source
RSS feed
Host
Labiotech
Beyond Biotech - the podcast from Labiotech
@beyondbiotechthepodcastfroml
#turningcancercell #targetedtherapies
